Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Condition:   Pulmonary Tuberculosis Interventions:   Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS);   Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS);   Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE);   Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) Sponsors:   Bill & Melinda Gates Medical Research Institute;   Global Alliance for TB Drug Development;   Janssen Pharmaceutica;   Otsuka Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials